<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d42">
    <sentence id="DDI-DrugBank.d42.s0" text="The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.">
        <entity id="DDI-DrugBank.d42.s0.e0" charOffset="73-82"
            type="drug" text="dolasetron"/>
        <entity id="DDI-DrugBank.d42.s0.e1" charOffset="88-102"
            type="drug_n" text="hydrodolasetron"/>
        <entity id="DDI-DrugBank.d42.s0.e2" charOffset="182-196"
            type="drug_n" text="hydrodolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s1" text="Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.">
        <entity id="DDI-DrugBank.d42.s1.e0" charOffset="16-30"
            type="drug_n" text="hydrodolasetron"/>
        <entity id="DDI-DrugBank.d42.s1.e1" charOffset="51-60"
            type="drug" text="dolasetron"/>
        <entity id="DDI-DrugBank.d42.s1.e2" charOffset="86-95"
            type="drug" text="cimetidine"/>
        <entity id="DDI-DrugBank.d42.s1.e3" charOffset="197-204"
            type="drug" text="rifampin"/>
        <ddi id="DDI-DrugBank.d42.s1.d0" e1="DDI-DrugBank.d42.s1.e1"
            e2="DDI-DrugBank.d42.s1.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d42.s1.d1" e1="DDI-DrugBank.d42.s1.e1"
            e2="DDI-DrugBank.d42.s1.e3" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s2" text="Dolasetron has been safely coadministered with drugs used in chemotherapy and surgery.">
        <entity id="DDI-DrugBank.d42.s2.e0" charOffset="0-9" type="drug" text="Dolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s3" text="As with other agents which prolong ECG intervals, caution should be exercised in patients taking drugs which prolong ECG intervals, particularly QTc."/>
    <sentence id="DDI-DrugBank.d42.s4" text="In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.">
        <entity id="DDI-DrugBank.d42.s4.e0" charOffset="19-28"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d42.s4.e1" charOffset="31-40"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d42.s4.e2" charOffset="43-51"
            type="drug" text="diltiazem"/>
        <entity id="DDI-DrugBank.d42.s4.e3" charOffset="54-67"
            type="group" text="ACE inhibitors"/>
        <entity id="DDI-DrugBank.d42.s4.e4" charOffset="70-78"
            type="drug" text="verapamil"/>
        <entity id="DDI-DrugBank.d42.s4.e5" charOffset="81-89"
            type="drug" text="glyburide"/>
        <entity id="DDI-DrugBank.d42.s4.e6" charOffset="92-102"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d42.s4.e7" charOffset="178-192"
            type="drug_n" text="hydrodolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s5" text="Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.">
        <entity id="DDI-DrugBank.d42.s5.e0" charOffset="13-27"
            type="drug_n" text="hydrodolasetron"/>
        <entity id="DDI-DrugBank.d42.s5.e1" charOffset="57-75"
            type="drug" text="dolasetron mesylate"/>
        <entity id="DDI-DrugBank.d42.s5.e2" charOffset="127-134"
            type="drug" text="atenolol"/>
        <ddi id="DDI-DrugBank.d42.s5.d0" e1="DDI-DrugBank.d42.s5.e1"
            e2="DDI-DrugBank.d42.s5.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s6" text="Dolasetron does not influence anesthesia recovery time in patients.">
        <entity id="DDI-DrugBank.d42.s6.e0" charOffset="0-9" type="drug" text="Dolasetron"/>
    </sentence>
    <sentence id="DDI-DrugBank.d42.s7" text="Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.">
        <entity id="DDI-DrugBank.d42.s7.e0" charOffset="0-18"
            type="drug" text="Dolasetron mesylate"/>
        <entity id="DDI-DrugBank.d42.s7.e1" charOffset="67-89"
            type="group" text="chemotherapeutic agents"/>
        <entity id="DDI-DrugBank.d42.s7.e2" charOffset="92-100"
            type="drug" text="cisplatin"/>
        <entity id="DDI-DrugBank.d42.s7.e3" charOffset="103-116"
            type="drug" text="5-fluorouracil"/>
        <entity id="DDI-DrugBank.d42.s7.e4" charOffset="119-129"
            type="drug" text="doxorubicin"/>
        <entity id="DDI-DrugBank.d42.s7.e5" charOffset="132-147"
            type="drug" text="cyclophosphamide"/>
    </sentence>
</document>
